nach oben

Abdominal Radiology

Erschienen in:

25.05.2020 | Review

Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists

verfasst von: Ali Pourvaziri, Anushri Parakh, Pierpaolo Biondetti, Dushyant Sahani, Avinash Kambadakone

Erschienen in: Abdominal Radiology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Immunotherapy is a rapidly growing field within oncology and is being increasingly used in the management of several malignancies. Due to their unique mechanism of action on the immune system and neoplastic cells, the response pattern and adverse events of this novel therapy are distinct from conventional systemic therapies. Accordingly, the imaging appearances following immunotherapy including adverse events are unique and at times perplexing. Imaging is integral to management of patients on immunotherapeutic agents and a thorough understanding of its mechanism, response patterns and adverse events is crucial for precise interpretation of imaging studies. This review provides a description of the mechanism of action of current immunotherapeutic agents and the organ-wise description of their side effects.

Wolchok J (2012) How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol 23:viii15–viii21. https://doi.org/10.1093/annonc/mds258

Ibrahim RA, Berman DM, DePril V, et al (2011) Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. JCO 29:8583–8583. https://doi.org/10.1200/jco.2011.29.15_suppl.8583CrossRef

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168:707–723. https://doi.org/10.1016/j.cell.2017.01.017CrossRefPubMedPubMedCentral

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer 12:252–264. https://doi.org/10.1038/nrc3239CrossRefPubMedPubMedCentral

Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350–1355. https://doi.org/10.1126/science.aar4060CrossRefPubMedPubMedCentral

Waldmann TA (2003) Immunotherapy: past, present and future. Nature Medicine 9:269–277. https://doi.org/10.1038/nm0303-269CrossRefPubMed

Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005. https://doi.org/10.1038/ni1102-999CrossRefPubMedPubMedCentral

Gajewski TF, Schreiber H, Fu Y-X (2013) Innate and adaptive immune cells in the tumor microenvironment. Nature Immunology 14:1014–1022. https://doi.org/10.1038/ni.2703CrossRefPubMedPubMedCentral

Caswell DR, Swanton C (2017) The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med 15:133. https://doi.org/10.1186/s12916-017-0900-yCrossRefPubMedPubMedCentral

10.

Mohme M, Riethdorf S, Pantel K (2017) Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol 14:155–167. https://doi.org/10.1038/nrclinonc.2016.144CrossRefPubMed

11.

Rodríguez PC, Zea AH, Ochoa AC (2003) Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol Response Modif 21:351–364CrossRefPubMed

12.

Amin A, White RL (2014) Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? J Kidney Cancer VHL 1:74–83. https://doi.org/10.15586/jkcvhl.2014.18CrossRefPubMedPubMedCentral

13.

Sharma P, Allison JP (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:205–214. https://doi.org/10.1016/j.cell.2015.03.030CrossRefPubMedPubMedCentral

14.

Muenst S, Läubli H, Soysal SD, et al (2016) The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 279:541–562. https://doi.org/10.1111/joim.12470CrossRefPubMed

15.

Walunas TL, Lenschow DJ, Bakker CY, et al (1994) CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405–413. https://doi.org/10.1016/1074-7613(94)90071-XCrossRefPubMed

16.

Intlekofer AM, Thompson CB (2013) At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 94:25–39. https://doi.org/10.1189/jlb.1212621CrossRefPubMedPubMedCentral

17.

Cancer immunotherapy using checkpoint blockade | Science. https://science-sciencemag-org.ezp-prod1.hul.harvard.edu/content/359/6382/1350. Accessed 22 Apr 2019

18.

Kantoff PW, Higano CS, Shore ND, et al (2010) Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine 363:411–422. https://doi.org/10.1056/NEJMoa1001294CrossRefPubMed

19.

Kochenderfer JN, Dudley ME, Kassim SH, et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540–549. https://doi.org/10.1200/JCO.2014.56.2025CrossRefPubMed

20.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528. https://doi.org/10.1016/S0140-6736(14)61403-3CrossRefPubMed

21.

Kaufman HL, Kirkwood JM, Hodi FS, et al (2013) The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588–598. https://doi.org/10.1038/nrclinonc.2013.153CrossRefPubMed

22.

Wolchok JD, Neyns B, Linette G, et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155–164. https://doi.org/10.1016/S1470-2045(09)70334-1CrossRefPubMed

23.

Ipilimumab: Developmental History, Clinical Considerations, and Future Perspectives - SkinCancer.org. https://www.skincancer.org/publications/the-melanoma-letter/spring-2012-vol-30-no-1/ipilmumab. Accessed 26 Apr 2019

24.

Tang YZ, Szabados B, Leung C, Sahdev A (2018) Adverse effects and radiological manifestations of new immunotherapy agents. Br J Radiol 20180164. https://doi.org/10.1259/bjr.20180164CrossRefPubMedPubMedCentral

25.

Calandri M, Solitro F, Angelino V, et al (2018) The role of radiology in the evaluation of the immunotherapy efficacy. J Thorac Dis 10:S1438–S1446. https://doi.org/10.21037/jtd.2018.05.130CrossRefPubMedPubMedCentral

26.

Som A, Mandaliya R, Alsaadi D, et al (2019) Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 7:405–418. https://doi.org/10.12998/wjcc.v7.i4.405CrossRefPubMedPubMedCentral

27.

Braschi-Amirfarzan M, Tirumani SH, Hodi FS, Nishino M (2017) Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean Journal of Radiology 18:42. https://doi.org/10.3348/kjr.2017.18.1.42CrossRefPubMedPubMedCentral

28.

Sosa A, Lopez Cadena E, Simon Olive C, et al (2018) Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 10:. https://doi.org/10.1177/1758835918764628CrossRefPubMedPubMedCentral

29.

Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166–182. https://doi.org/10.1111/j.1600-065X.2008.00662.xCrossRefPubMed

30.

Handy CE, Antonarakis ES (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907–917. https://doi.org/10.2217/fon-2017-0531CrossRefPubMed

31.

O’Regan KN, Jagannathan JP, Ramaiya N, Hodi FS (2011) Radiologic Aspects of Immune-Related Tumor Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Ipilimumab Therapy. American Journal of Roentgenology 197:W241–W246. https://doi.org/10.2214/AJR.10.6032CrossRefPubMed

32.

Gonzalez RS, Salaria SN, Bohannon CD, et al (2017) PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis.’ Histopathology 70:558–567. https://doi.org/10.1111/his.13118CrossRefPubMed

33.

Kumar V, Chaudhary N, Garg M, et al (2017) Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol https://doi.org/10.3389/fphar.2017.00049CrossRefPubMedPubMedCentral

34.

Reddy HG, Schneider BJ, Tai AW (2018) Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clin Transl Gastroenterol https://doi.org/10.1038/s41424-018-0049-9CrossRefPubMedPubMedCentral

35.

Horvat TZ, Adel NG, Dang T-O, et al (2015) Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193–3198. https://doi.org/10.1200/JCO.2015.60.8448CrossRefPubMedPubMedCentral

36.

Mohamed AA, Richards CJ, Boyle K, Faust G (2018) Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Reports bcr-2018-224913. https://doi.org/10.1136/bcr-2018-224913

37.

Velasco GD, Je Y, Bossé D, et al (2017) Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 5:312–318. https://doi.org/10.1158/2326-6066.CIR-16-0237CrossRefPubMedPubMedCentral

38.

Weber J, Thompson JA, Hamid O, et al (2009) A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clin Cancer Res 15:5591–5598. https://doi.org/10.1158/1078-0432.CCR-09-1024CrossRefPubMed

39.

Zhang B, Wu Q, Zhou YL, et al (2018) Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. International Immunopharmacology 63:292–298. https://doi.org/10.1016/j.intimp.2018.08.014CrossRefPubMed

40.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:23–34. https://doi.org/10.1056/NEJMoa1504030CrossRefPubMedPubMedCentral

41.

Haanen JB a. G, Carbonnel F, Robert C, et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142. https://doi.org/10.1093/annonc/mdx225

42.

Wang GX, Kurra V, Gainor JF, et al (2017) Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics 37:2132–2144. https://doi.org/10.1148/rg.2017170085CrossRefPubMed

43.

Michot J-M, Ragou P, Carbonnel F, et al (2018) Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication. J Immunother 41:84–85. https://doi.org/10.1097/CJI.0000000000000202CrossRefPubMed

44.

Bronstein Y, Ng CS, Hwu P, Hwu W-J (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992–W1000. https://doi.org/10.2214/AJR.10.6198CrossRefPubMed

45.

Gupta A, Felice KMD, Loftus EV, Khanna S (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Alimentary Pharmacology & Therapeutics 42:406–417. https://doi.org/10.1111/apt.13281CrossRef

46.

Barina AR, Bashir MR, Howard BA, et al (2016) Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol 41:207–214. https://doi.org/10.1007/s00261-015-0560-3CrossRef

47.

Tirumani SH, Ramaiya NH, Keraliya A, et al (2015) Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunology Research 3:1185–1192. https://doi.org/10.1158/2326-6066.CIR-15-0102CrossRefPubMedPubMedCentral

48.

Nishino M, Tirumani SH, Ramaiya NH, Hodi FS (2015) Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology 84:1259–1268. https://doi.org/10.1016/j.ejrad.2015.03.017CrossRefPubMedPubMedCentral

49.

Kim KW, Ramaiya NH, Krajewski KM, et al (2013) Ipilimumab-Associated Colitis: CT Findings. American Journal of Roentgenology 200:W468–W474. https://doi.org/10.2214/AJR.12.9751CrossRefPubMed

50.

Beck KE, Blansfield JA, Tran KQ, et al (2006) Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. J Clin Oncol 24:2283–2289. https://doi.org/10.1200/JCO.2005.04.5716CrossRefPubMed

51.

Carter BW, Bhosale PR, Yang WT (2018) Immunotherapy and the role of imaging. Cancer 124:2906–2922. https://doi.org/10.1002/cncr.31349CrossRefPubMed

52.

Lord JD, Hackman RC, Moklebust A, et al (2010) Refractory Colitis Following Anti-CTLA4 Antibody Therapy; Analysis of Mucosal FOXP3 + T Cells. Dig Dis Sci 55:1396–1405. https://doi.org/10.1007/s10620-009-0839-8CrossRefPubMed

53.

Verschuren EC, van den Eertwegh AJ, Wonders J, et al (2016) Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clinical Gastroenterology and Hepatology 14:836–842. https://doi.org/10.1016/j.cgh.2015.12.028CrossRefPubMed

54.

Geukes Foppen MH, Rozeman EA, van Wilpe S, et al (2018) Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3:. https://doi.org/10.1136/esmoopen-2017-000278CrossRefPubMedPubMedCentral

55.

Venditti O, De Lisi D, Caricato M, et al (2015) Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. BMC Cancer 15:. https://doi.org/10.1186/s12885-015-1074-7CrossRefPubMedPubMedCentral

56.

Nishino M, Hatabu H, Hodi FS (2018) Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. Radiology 290:9–22. https://doi.org/10.1148/radiol.2018181349CrossRefPubMed

57.

Alessandrino F, Tirumani SH, Krajewski KM, et al (2017) Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clinical Radiology 72:521–533. https://doi.org/10.1016/j.crad.2017.04.003CrossRefPubMed

58.

Kim M, Yi R, Cho K-S, Choi HJ (2014) Three-phase, contrast-enhanced, multidetector CT in the evaluation of complicated renal cysts: comparison of the postcontrast phase combination. Acta Radiol 55:372–377. https://doi.org/10.1177/0284185113495837CrossRefPubMed

59.

Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors - ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0168827818300837. Accessed 29 Apr 2019

60.

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab | Journal of Clinical Oncology. https://ascopubs.org/doi/full/10.1200/JCO.2012.41.6750. Accessed 29 Apr 2019

61.

Min JH, Lee HY, Lim H, et al (2011) Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 68:1099–1109. https://doi.org/10.1007/s00280-011-1737-2CrossRefPubMed

62.

Kim KW, Ramaiya NH, Krajewski KM, et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071–1077. https://doi.org/10.1007/s10637-013-9939-6CrossRefPubMed

63.

Kwak JJ, Tirumani SH, Van den Abbeele AD, et al (2015) Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events. RadioGraphics 35:424–437. https://doi.org/10.1148/rg.352140121CrossRefPubMed

64.

Suzman DL, Pelosof L, Rosenberg A, Avigan MI (2018) Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International 38:976–987. https://doi.org/10.1111/liv.13746CrossRefPubMed

65.

Widmann G, Nguyen VA, Plaickner J, Jaschke W (2016) Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy. Curr Radiol Rep 5:59. https://doi.org/10.1007/s40134-017-0256-2CrossRefPubMed

66.

Gelsomino F, Vitale G, D’Errico A, et al (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671–672. https://doi.org/10.1093/annonc/mdw649CrossRefPubMed

67.

Kawakami H, Tanizaki J, Tanaka K, et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529–536. https://doi.org/10.1007/s10637-017-0453-0CrossRefPubMed

68.

Gelsomino F, Vitale G, Ardizzoni A (2018) A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs 36:144–146. https://doi.org/10.1007/s10637-017-0484-6CrossRefPubMed

69.

Abu-Sbeih H, Tran CN, Ge PS, et al (2019) Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. Journal for ImmunoTherapy of Cancer 7:. https://doi.org/10.1186/s40425-019-0604-2CrossRefPubMedPubMedCentral

70.

Cho JH, Sun J-M, Lee S-H, et al (2018) Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology 13:e34–e36. https://doi.org/10.1016/j.jtho.2017.10.007CrossRefPubMed

71.

Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunology, Immunotherapy 67:61–65. https://doi.org/10.1007/s00262-017-2062-3CrossRefPubMed

72.

Su Q, Zhang X-C, Zhang C-G, et al (2018) Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. J Immunol Res 2018:1027323. https://doi.org/10.1155/2018/1027323CrossRefPubMedPubMedCentral

73.

Abu-Sbeih H, Tang T, Lu Y, et al (2019) Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 7:31. https://doi.org/10.1186/s40425-019-0502-7CrossRefPubMedPubMedCentral

74.

Okamoto M, Okamoto M, Gotoh K, et al (2016) Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. Journal of Diabetes Investigation 7:915–918. https://doi.org/10.1111/jdi.12531CrossRefPubMedPubMedCentral

75.

Munakata W, Ohashi K, Yamauchi N, Tobinai K (2017) Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol 105:383–386. https://doi.org/10.1007/s12185-016-2101-4CrossRefPubMed

76.

Di Giacomo AM, Danielli R, Guidoboni M, et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306. https://doi.org/10.1007/s00262-008-0642-yCrossRefPubMed

77.

Kohlmann J, Wagenknecht D, Simon JC, Ziemer M (2019) Immune-related pancreatitis associated with checkpoint blockade in melanoma. Melanoma Res. https://doi.org/10.1097/CMR.0000000000000611CrossRefPubMed

78.

Hofmann L, Forschner A, Loquai C, et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. European Journal of Cancer 60:190–209. https://doi.org/10.1016/j.ejca.2016.02.025CrossRefPubMed

79.

Fadel F, Karoui KE, Knebelmann B (2009) Anti-CTLA4 Antibody–Induced Lupus Nephritis. New England Journal of Medicine 361:211–212. https://doi.org/10.1056/NEJMc0904283CrossRefPubMed

80.

Hamid O, Robert C, Daud A, et al (2013) Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma. N Engl J Med 369:134–144. https://doi.org/10.1056/NEJMoa1305133CrossRefPubMedPubMedCentral

81.

Wolchok JD, Kluger H, Callahan MK, et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133. https://doi.org/10.1056/NEJMoa1302369CrossRefPubMedPubMedCentral

82.

Cortazar FB, Marrone KA, Troxell ML, et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638–647. https://doi.org/10.1016/j.kint.2016.04.008CrossRefPubMedPubMedCentral

83.

Jung K, Zeng X, Bilusic M (2016) Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol 17:. https://doi.org/10.1186/s12882-016-0408-2CrossRefPubMedPubMedCentral

84.

Murakami N, Borges TJ, Yamashita M, Riella LV (2016) Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J 9:411–417. https://doi.org/10.1093/ckj/sfw024CrossRefPubMedPubMedCentral

85.

Vandiver JW, Singer Z, Harshberger C (2016) Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. Targ Oncol 11:553–556. https://doi.org/10.1007/s11523-016-0426-9CrossRef

86.

Bickel A, Koneth I, Enzler-Tschudy A, et al (2016) Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer 16:. https://doi.org/10.1186/s12885-016-2718-yCrossRefPubMedPubMedCentral

87.

Forde PM, Rock K, Wilson G, O’byrne KJ (2012) Ipilimumab-induced Immune-related Renal Failure – A Case Report. Anticancer Res 32:4607–4608PubMed

88.

Izzedine H, Gueutin V, Gharbi C, et al (2014) Kidney injuries related to ipilimumab. Invest New Drugs 32:769–773. https://doi.org/10.1007/s10637-014-0092-7CrossRefPubMed

89.

Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology 13:195–207. https://doi.org/10.1038/nrendo.2016.205CrossRefPubMedPubMedCentral

90.

Torino F, Corsello SM, Salvatori R (2016) Endocrinological side-effects of immune checkpoint inhibitors: Current Opinion in Oncology 28:278–287. https://doi.org/10.1097/CCO.0000000000000293CrossRefPubMed

91.

Bacanovic S, Burger IA, Stolzmann P, et al (2015) Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT. Clinical Nuclear Medicine 40:e518–e519. https://doi.org/10.1097/RLU.0000000000000887CrossRefPubMed

92.

Min L, Ibrahim N (2013) Ipilimumab immunotherapy for advanced melanoma induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 1:e15. https://doi.org/10.1016/S2213-8587(13)70031-7CrossRefPubMedPubMedCentral

93.

Trainer H, Hulse P, Higham CE, et al (2016) Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep 2016:. https://doi.org/10.1530/EDM-16-0108CrossRefPubMedPubMedCentral

94.

Abdel-Rahman O, Eltobgy M, Oweira H, et al (2017) Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy 9:1175–1183. https://doi.org/10.2217/imt-2017-0108CrossRefPubMed

95.

Cappelli LC, Gutierrez AK, Bingham CO, Shah AA (2017) Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care Res (Hoboken) 69:1751–1763. https://doi.org/10.1002/acr.23177CrossRef

96.

Cappelli LC, Shah AA, Bingham CO (2017) Immune-related adverse effects of cancer immunotherapy- Implications for rheumatology. Rheum Dis Clin North Am 43:65–78. https://doi.org/10.1016/j.rdc.2016.09.007CrossRefPubMed

97.

Cappelli LC, Gutierrez AK, Baer AN, et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76:43–50. https://doi.org/10.1136/annrheumdis-2016-209595CrossRefPubMed

98.

Chan MMK, Kefford RF, Carlino M, et al (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38:37–39. https://doi.org/10.1097/CJI.0000000000000060CrossRefPubMed

99.

Albayda J, Bingham CO, Shah AA, et al (2018) Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatology (Oxford) 57:760–762. https://doi.org/10.1093/rheumatology/kex470CrossRef

100.

Daoussis D, Kraniotis P, Liossis S-N, Solomou A (2017) Immune checkpoint inhibitor-induced myo-fasciitis. Rheumatology (Oxford) 56:2161–2161. https://doi.org/10.1093/rheumatology/kex369CrossRef

101.

Narváez J, Juarez-López P, LLuch J, et al (2018) Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmunity Reviews 17:1040–1045. https://doi.org/10.1016/j.autrev.2018.05.002CrossRefPubMed

102.

Reule RB, North JP (2013) Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. Journal of the American Academy of Dermatology 69:e272–e273. https://doi.org/10.1016/j.jaad.2013.07.028CrossRefPubMed

103.

Lomax AJ, McGuire HM, McNeil C, et al (2017) Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. International Journal of Rheumatic Diseases 20:1277–1285. https://doi.org/10.1111/1756-185X.13076CrossRefPubMed

104.

Reddy SB, Possick JD, Kluger HM, et al (2017) Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma. J Immunother 40:307–311. https://doi.org/10.1097/CJI.0000000000000181CrossRefPubMed

105.

Danlos F-X, Pagès C, Baroudjian B, et al (2016) Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma. Chest 149:e133–e136. https://doi.org/10.1016/j.chest.2015.10.082CrossRefPubMed

106.

Le Burel S, Champiat S, Mateus C, et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. European Journal of Cancer 82:34–44. https://doi.org/10.1016/j.ejca.2017.05.032CrossRefPubMed

107.

Firwana B, Ravilla R, Raval M, et al (2017) Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 23:620–624. https://doi.org/10.1177/1078155216667635CrossRefPubMed

108.

Cheshire SC, Board RE, Lewis AR, et al (2018) Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma. Radiology 289:564–567. https://doi.org/10.1148/radiol.2018180572CrossRefPubMed

Titel: Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists
verfasst von: Ali Pourvaziri
Anushri Parakh
Pierpaolo Biondetti
Dushyant Sahani
Avinash Kambadakone
Publikationsdatum: 25.05.2020
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 9/2020
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-020-02531-5

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists

Abstract

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Higher frequency of hepatic steatosis at CT among COVID-19-positive patients

Portosystemic shunt surgery in the era of TIPS: imaging-based planning of the surgical approach

Blood supply to the caudate lobe of the liver from the right inferior phrenic artery: observation by cone-beam computed tomography during arteriography

Quantification of pancreas fat on dual-energy computed tomography: comparison with six-point Dixon magnetic resonance imaging

Characterization of solid renal neoplasms using MRI-based quantitative radiomics features

Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Neu im Fachgebiet Radiologie

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Radiologie